Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hanson
Lianyungang, Jiangsu, China
- Ownership
- Private
- Employees
- ~6000
- Development stage
- Other
01
Overview
Hansoh Pharma has more than 70 clinical trials in progress and over 40 pipeline drug candidates; 7 innovative drugs approved, 9 indications in NRDL (China’s reimbursement list). Major international expansion, first original third-gen EGFR inhibitor (aumolertinib) launched in China and UK. PEGylated GLP-1 drug and innovative peptide for renal anemia are globally first-in-class/unmet-need medicines
- Therapeutic areas
- NephrologyEndocrinologyInfectious DiseasesOtherOncology
- Modalities
- Small moleculePeptidesAntibody-drug conjugateBispecific monoclonal antibodysiRNA therapy
- Industry
- Biotech
02
Partnerships
GSKMSD (Merck & Co.)Regeneronmultiple in- and out-licensing collaborations
Beyond the preview
Go deeper on Hanson.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hanson.